• Press conference held on Thursday, Oct. 28 at 1:00 p.m. ET at the Loews Hotel.
• New DNA methylation test may change screening landscape.
• Emerging targeted treatments show promise in hard to treat cases.
PHILADELPHIA — The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.
Colorectal cancer is the third leading cause of cancer in men and women. While screening has brought mortality rates down, much work remains to be done.
“Colorectal cancer is still one of the deadliest cancers, and our current screening methods are not yet always efficient or complete,” said Anil Rustgi, M.D., chief of gastroenterology, T. Grier Miller Professor of Medicine and Genetics, and American Cancer Society Professor at the University of Pennsylvania School of Medicine and a program chairperson of the AACR special conference.
Rustgi will host a press conference featuring new research on Thursday, Oct. 28 at 1:00 p.m. ET in the Adams Room on the third floor of the Loews Hotel in Philadelphia.
Reporters who cannot attend in person can participate using the following information:
Dial-in (U.S. and Canada): (888) 282-7404
Dial-in (International): (706) 679-5207
Access Code: 18304706
The American Association for Cancer Research Communications Department will post press releases from the press conference and additional research onto the Public & Media area of the website.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Loews Hotel, Phila., Oct. 27-30: